Life Science Today

Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs.

Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

The Niche Episode 016 – Slow, Sickle-Cell, CRO Mergers, Praxis IPO, Wasp Venom

Failures in sickle-cell therapy, CRO mergers in Asia, Praxis IPO, and wasp venom.

Sponsors

https://www.thescopemethod.com

Story References

https://ir.cyclerion.com/news-releases/news-release-details/cyclerion-announces-phase-2-strong-scd-study-results-patients

https://ir.cyclerion.com/news-releases/news-release-details/cyclerion-announces-positive-data-iw-6463-cns-translational

https://novotech-cro.com/news/asia-pacific-has-record-year-clinical-trials-according-novotech 

https://investors.praxismedicines.com/press-releases

https://www.pnas.org/content/early/2020/10/07/2012379117

Music by Luke Goodson

https://www.soundcloud.com/lukegoodson

 The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

The Niche Episode 015 – CRISPR, Tinnitus, Takeda, and Political-Science

Nobel prizes, clinical trials for tinnitus, Takeda’s billion-dollar deal, and the White House keeps science political

Sponsors
https://www.thescopemethod.com

Story References
https://www.nobelprize.org/prizes/chemistry/2020/summary/
https://stm.sciencemag.org/content/12/564/eabb2830
https://www.nytimes.com/2020/10/05/us/politics/coronavirus-vaccine-guidelines.html
https://www.businesswire.com/news/home/20201008005340/en/

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

The Niche Episode 014 – Bristol Myers, Trump, NIH, and Sophia Genetics

Bristol Myers strikes a $13 billion deal, presidential experiments, the NIH funds under-represented testing, and Sophia Genetics raises $110 million.

Sponsors

https://www.thescopemethod.com

  

Story References

https://www.businesswire.com/news/home/20201005005381/en/Bristol-Myers-Squibb-to-Acquire-MyoKardia-for-13.1-Billion-in-Cash
https://www.sciencemag.org/news/2020/10/heres-what-known-about-president-donald-trump-s-covid-19-treatment
https://www.nih.gov/news-events/news-releases/nih-assess-expand-covid-19-testing-underserved-communities
https://www.sophiagenetics.com/en_US/news/media-mix/details/news/sophia-genetics-raises-110-million-in-oversubscribed-new-funding-round.html

 

 Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

The Niche Episode 013 – Alzheimer’s, COVID19, AKG, Vitamin D, and Gene Therapy

Another Alzheimer’s failure, COVID19 updates, two stories in the supplements space, and Taysha goes public.

Sponsors

https://www.thescopemethod.com

Story References

https://ir.acimmune.com/news-releases/news-release-details/ac-immune-reports-top-line-results-tauriel-phase-2-trial

https://www.medrxiv.org/content/10.1101/2020.09.23.20199604v1.full.pdf

https://www.cell.com/cell-metabolism/fulltext/S1550-4131(20)30417-4

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239799

https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-pricing-initial-public-offering

Music by Luke Goodson

https://www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

The Niche Episode 012 – Probiotics, Lipid Nanoparticles, Transparency, and Immuno-therapy

Finch does probiotics the expensive way, lipid nanoparticles, a followup on transparency, and LAVA gains immuno-therapy support.

Sponsors
https://www.thescopemethod.com

 

Story References
https://www.businesswire.com/news/home/20200916005915/en/Moderna-and-Vertex-Establish-New-Collaboration-to-Treat-Cystic-Fibrosis-Using-Gene-Editing

https://finchtherapeutics.com/blog/finch-therapeutics-announces-90-million-financing

https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf

https://www.businesswire.com/news/home/20200916005913/en/LAVA-Therapeutics-Announces-83-million-Series-C-Financing-to-Advance-Novel-Immuno-Oncology-Programs


Music by Luke Goodson

https://www.soundcloud.com/lukegoodson

The Niche Episode 011 – AstraZeneca, Satsuma Pharmaceuticals, and Orasis Pharmaceuticals

This week, vaccines and shark statistics, are noses the ultimate pipedream, and eye drops to replace eye-glasses.

Sponsors

https://www.thescopemethod.com

 

Story References

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/statement-on-astrazeneca-oxford-sars-cov-2-vaccine-azd1222-covid-19-vaccine-trials-temporary-pause.html

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/covid-19-vaccine-azd1222-clinical-trials-resumed-in-the-uk.html

https://www.globenewswire.com/news-release/2020/09/10/2091685/0/en/Satsuma-Pharmaceuticals-Announces-Topline-Results-from-EMERGE-Phase-3-Trial-of-STS101-for-the-Acute-Treatment-of-Migraine.html

https://www.orasis-pharma.com/orasis-raises-30-million-to-advance-the-clinical-development-of-novel-treatment-for-presbyopia/

 

Music by Luke Goodson

https://www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.

Responses

About Instructor

If you'd like to comment on this course or lecture please Register or Login.

THIS CONTENT IS FOR

Registered Users

Please login or register to continue.